C-Rad ABLTS:0R44 87 Pretax Margin % is 13.66% as of Mar. 2026, which is 155% above its 10-year median of 5.36. GuruFocus rates LTS:0R44 with a GF Score™ of 87/100 and a GF Value™ of kr33.49 (Fairly Valued). The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, C-Rad AB ranks better than 64.99% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. C-Rad AB's Pre-Tax Income for the
three
months ended in Mar. 2026 was kr14.3 Mil. C-Rad AB's Revenue for the
three
months ended in Mar. 2026 was kr104.7 Mil. Therefore, C-Rad AB's pretax margin for the quarter that ended in Mar. 2026 was 13.66%.
The historical rank and industry rank for C-Rad AB's Pretax Margin % or its related term are showing as below:
LTS:0R44'
s Pretax Margin % Range Over the Past 10 Years
Min: -37.76 Med: 5.36 Max: 17.01
Current: 8.86
LTS:0R44's Pretax Margin % is ranked better than 64.99% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs LTS:0R44: 8.86
C-Rad AB (LTS:0R44) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
C-Rad AB Pretax Margin % Related Terms
C-Rad AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for C-Rad AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R44 vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, C-Rad AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where C-Rad AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-Rad AB (LTS:0R44) has a Pretax Margin % of 13.66% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on C-Rad AB and its competitors. This is 155% above median its historical median of 5.36. According to the industry distribution chart, C-Rad AB ranks #286 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 35%.
Is C-Rad AB's Pretax Margin % too high?
C-Rad AB's current Pretax Margin % of 13.66% is 155% above median its 10-year median of 5.36. The Medical Devices & Instruments industry median Pretax Margin % is 2.40. C-Rad AB's value of 13.66% is 469.2% above this industry median. Based on the distribution chart, C-Rad AB ranks #286 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, C-Rad AB has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #286 out of 817 companies for Pretax Margin %. This puts C-Rad AB in the upper half of its industry. The industry median Pretax Margin % is 2.40. C-Rad AB's value of 13.66% is 469.2% above this benchmark. While the company's 10-year median is 5.36 vs. the industry median of 2.40, C-Rad AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.40, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current Pretax Margin % of 13.66% is 469.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current Pretax Margin % is 13.66%, which is 155% above median its own 10-year median of 5.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.49, compared to a current price of kr35.90 — trading 7.2% above its estimated fair value. The current Pretax Margin % is 13.66%, which is 155% above median its 10-year median of 5.36 and 469.2% above the Medical Devices & Instruments industry median of 2.40. C-Rad AB's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current Pretax Margin % is 13.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr35.90 is trading 7.2% above its estimated GF Value™ of kr33.49.
GuruFocus considers C-Rad AB to be Fairly Valued.
Key valuation signals for LTS:0R44:
Pretax Margin %: 13.66% (155% above median its 10-year median of 5.36)
GF Value™: kr33.49 vs. price of kr35.90 (7.2% above fair value)
Industry Position: 469.2% above the Medical Devices & Instruments median (#286 of 817)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
87GF Score
Get the complete analysis for LTS:0R44
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
